首页> 外文OA文献 >HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

【2h】

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

机译：HER2和TOP2A作为含蒽环类化疗方案作为乳腺癌辅助治疗的预测指标：对单个患者数据的荟萃分析。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Prediction of response to anthracycline-based therapy for breast cancer is challenging. We aimed to assess the value of HER2 and TOP2A as predictive markers of response to anthracycline-based adjuvant therapy in patients with early breast cancer.

机译：对基于蒽环类药物的乳腺癌治疗反应的预测具有挑战性。我们旨在评估HER2和TOP2A作为早期乳腺癌患者对基于蒽环类的辅助治疗反应的预测指标的价值。

著录项

作者
Di Leo, Angelo; Desmedt, Christine; Bartlett, John M S; Piette, Fanny; Ejlertsen, Bent; Pritchard, Kathleen; Larsimont, Denis; Poole, Christopher; Isola, Jorma; Earl, Helena; Mouridsen, Henning; O'Malley, Frances P; Cardoso, Fatima; Tanner, Minna; Munro, Alison; Twelves, Chris J; Sotiriou, Christos; Shepherd, Lois; Cameron, David A; Piccart-Gebhart, Martine; Buyse, Marc; HER2/TOP2A Meta-analysis Study Group;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献
专利

1. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. [J] . Di Leo A, Desmedt C, Bartlett JM, The lancet oncology . 2011,第12期

机译：HER2和TOP2A作为含蒽环类化疗方案作为乳腺癌辅助治疗的预测指标：对单个患者数据的荟萃分析。
2. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. [J] . Ejlertsen B, Jensen MB, Nielsen K Journal of Clinical Oncology . 2010,第6期

机译：HER2，TOP2A和TIMP-1在高危乳腺癌患者中对含蒽环类辅助化疗的反应性。
3. 213 Duplication of chromosome 17 CEP predicts for anthracycline benefit: evidence from an international meta-analysis of 4 adjuvant breast cancer trials for the HER2/TOP2A meta-analysis study group [J] . J.M.S.Bartlett, A.Munro, F.P.OMalley, European Journal of Cancer Supplements . 2010,第3期

机译：213第17号染色体重复CEP预测蒽环类药物的获益：来自对HER2 / TOP2A荟萃分析研究组进行的4项辅助乳腺癌试验的国际荟萃分析的证据
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. The Effects of Adjuvant Chemotherapy on Brain Function in Breast Cancer Patients and a Cancer-Chemotherapy Rodent Model. [D] . Barr, Alicia Thomas. 2014

机译：辅助化疗对乳腺癌患者脑功能的影响和癌症化学疗法的啮齿动物模型。
6. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials [O] . George Fountzilas, Urania Dafni, Mattheos Bobos, 2013

机译：评价含着蒽环类辅助化疗的乳腺癌患者着丝粒17的获得和HER2 /拓扑异构酶IIα基因的状态及蛋白表达的预后作用：两项希腊合作肿瘤小组（HeCOG）III期临床试验的合并分析
7. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data [O] . Leo Angelo Di, Desmedt Christine, Bartlett John M S, 2011

机译：HER2和TOP2A作为含蒽环类化疗方案作为乳腺癌辅助治疗的预测标志物：单个患者数据的荟萃分析

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅